Skip to main content

Table 1 FoundationOne™ genomic testing identified three driver mutations, of which two were actionable with available drugs

From: Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease

Therapeutic Implications
Genomic Alteration FDA-approved therapies for ovarian cancer FDA-approved therapies for other tumor types
KRAS None Trametinib
PIK3CA None Everolimus, temsirolimus
TERT None None
 Promoter 124 C > T